Research summary ·
Efficacy and Safety of Romiplostim in the Treatment of Aplastic Anemia: A Systematic Review and Single-Arm Meta-Analysis.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This review looked at the drug romiplostim for aplastic anemia. The team searched several research databases up to March 3, 2026. They pooled results from earlier studies with 382 people in total. In each pooled result, all people got the drug. There was no group without the drug to compare with. The team also checked the quality of each study.
What they found
Many people had some response to the drug. Fewer people had a full response. People on 20 μg/kg did better than people on 10 μg/kg. People under 60 had more responses than people aged 60 or above. The rate of people who stopped the drug was low. No deaths were linked to the drug.
What it means for patients
The authors say romiplostim seems to work and to be safe in aplastic anemia. They say results were better at the 20 μg/kg dose. They also saw better results in younger people. They say more trials of high quality are still needed.
Why it is not certain yet
The gaps by dose and by age may not be firm. The abstract gives P values of 0.081 and 0.298 for them. The pooled studies had no group without the drug. So it is hard to tell what the drug alone did. The total number of people was 382. A review can only be as good as the studies in it.
Source
Efficacy and Safety of Romiplostim in the Treatment of Aplastic Anemia: A Systematic Review and Single-Arm Meta-Analysis.
PubMed · PMID 42268485We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Aplastic anaemia publications